X4 Pharmaceuticals, Inc: Deep Track Capital, LP amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Deep Track Capital, LP amended its Schedule 13G filing for X4 Pharmaceuticals, Inc., according to SEC accession 0001172661-26-005081. The filing updates the institutional investor's reported stake in the clinical-stage biopharmaceutical company. The amendment signals a change in Deep Track's position, though the filing summary did not disclose the revised share count or percentage. Investors will watch for the full filing details to gauge whether the adjustment reflects accumulation or reduction.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
X4 Pharmaceuticals, Inc., Deep Track Capital, LP